Bullfrog AI and Lieber Institute identify novel drug targets for neuropsychiatric disorders

BullFrog AI Holdings, Inc.

Identified dozens of patient clusters for depression, schizophrenia, and bipolar disorder using bfLEAP AI platform.
Key genes pinpointed for each cluster as potential drug targets; now applying Causal AI for validation.
Engagement initiated with pharmaceutical companies to secure strategic partnerships in coming quarters.
Collaboration leverages LIBD's brain data from over 2,800 samples under a three-year exclusive agreement.
Findings build on September 2023 partnership and January 2024 stratification results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.